Women Healthcare Market : Global Industry Analysis and Forecast (2024-2030)

The Women Healthcare Market size was valued at USD 33.35 Billion in 2023 and the total Women Healthcare Market revenue is expected to grow at a CAGR of 7.36 % from 2024 to 2030, reaching nearly USD 54.83Billion.
Women Healthcare Market Overview
The Women Healthcare Market involving women’s healthcare products and services has undergone a drastic change over decades considering certain factors constituting the market today and recent advancements by key players in the industry. Women’s healthcare entity is an extensive array of health and medical care services and products specially developed to satisfy the special health needs of women of all ages and stages. All clinical specialities such as gynecology, obstetrics, reproductive medicine, endocrinology, and psychiatry are facilitated through it. Thus, increasing rates of chronic diseases and changing demographics especially regarding women’s health concerns are the potential avenues for growth.



The rising incidences of chronic diseases and cancer in women are primary factors that have motivated the development of new therapies to treat such diseases hence expelling the market for women’s healthcare. Besides, the global awareness of female health matters and more advancement of products in the pharmaceutical industry will augment the demand for new treatments. Key competitors in this Women Healthcare Market have been active in strategic development and acquisitions to expand their portfolios and worldwide reach. These collaborative efforts, which include acquisition, technical improvement, and a focus on healthcare, aim to address the expanding need in the women's healthcare sector. Women confront several barriers while seeking healthcare, which shows in various diseases and areas of society. The research report covers women's health as including both sex-specific illnesses (e.g., endometriosis and menopause) and general health issues that may impact women differently (greater disease burden) or disproportionately (higher prevalence).

To know about the Research Methodology :- Request Free Sample Report
Women Healthcare Market Dynamics
Opportunities

The role of technology & Global Initiatives in Expanding Access to Healthcare

The Women Healthcare Market is on the edge of substantial changes for the advancement of healthcare access. There is also improved Healthcare access through technology this is due to telehealth, which means the delivery of healthcare services through the use of communication technology for example use of video conferencing, clinical telephone consultations, and remote patient monitoring. Telemedicine is especially important in rural and regions of poverty where access to basic women's healthcare is critical; nevertheless, as demand grows, telemedicine is reaching out to rural and non-privileged groups, as well as persons with limited mobility or chronic diseases. Dedicated to the use of technology at one’s disposal, health information, education, and data tracking are now available in applications and wearable devices.

Governments in countries across the globe are now attempting to expand women’s reproductive health through enhancements in funding for programs for the provision of both primary and precautionary services that include family planning, maternal and neonatal, cervical and breast cancer, and screenings and treatments. Every country has ministerial and localized programs that educate women and their male counterparts on birth control. Family planning falls under women’s health needs as it enables them to control their family planning and thus reduce cases of unwanted pregnancies. Many countries are making contraception more inexpensive and accessible. There is a lack of healthcare providers who are trained in women's healthcare, especially in rural and those in need in the Women Healthcare Market .
Many governments are producing more doctors and nurses for women to ensure they get the care they need. Sources of funding include the World Health Organization (WHO) and the United Nations Population Fund (UNFPA) to fund the development of family planning, maternal and child health as well as screening and treatment and cervical and breast cancer. Certain programs are launched for the deprived and backward villages to spread awareness among women about diseases and women's health. Empowering women is critical to increasing their access to healthcare. This involves informing women about their health rights and alternatives, as well as encouraging them to seek treatment, when necessary, which raises demand in the Women Healthcare Market .

Challenge

Neglecting Women's Health

For decades, clinical research was conducted mostly on males, with outcomes extended to women. It established a pattern of neglecting women's health. It wasn't until 1993 that medical studies began to involve women and identify sex/gender differences. The medical model is based on one gender: males. Understanding that women and men are physiologically different has resulted in the detection of disparities in women's health outcomes. Closing these inequalities will improve women's health and cut medical expenses. More than 20 years of studies reveal that female physiology differs significantly from that of males. Nonetheless, the majority of equipment and therapies are still geared toward male physiology. There are poorer diagnostic yields and compliance rates [among women] because devices are uncomfortable in the Women Healthcare Market .

Sociocultural factors that restrict women and girls from accessing adequate health care and achieving good health.


Women Healthcare Market Segment Analysis
Based on Drugs`

The Women Healthcare Market is divided based on drugs such as Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, and ORTHO TRI-CY LO (28). Prolia is now the fastest-growing category within the women’s health care organization segment and it shall be the market leader in 2023. Nevertheless, Prolia and XGEVA are antibodies that bind to RANKL, a protein that facilitates bone repair. The growing number of patients who require treatment with Prolia and XGEVA to prevent osteoporosis in women and other diseases like multiple myeloma and cancer-related bone pain is the main factor behind the market growth.
Like all medications in the SERM family, EVISTA will act as estrogen in some tissues while acting as an anti-estrogen in others. It is employed to treat and prevent postmenopausal osteoporosis, thus making this component applicable to numerous treatments. It is also being tested for the prevention of breast cancer as well as its particular treatment. Mirena is a hormonal IUD that stands out due to its effectiveness in preventing conception from coming through.: H; It is also applied in the management of postpartum haemorrhage, which is excessive bloody flow during menstruation. Zometa is on the list of drugs that are prescribed for osteoporosis, multiple myeloma and on occasion Paget’s disease. It is also indicated for the management of hyperkalaemia which is a state of excessive calcium in the blood. Zometa works in a way that is opposite to bone breakdown which in turn helps in reducing fractures.

Based on Application

According to analytical data, the postmenopausal osteoporosis category accounted for the largest share of the Women Healthcare Market in 2023 in terms of applications. Hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and others are the key segments of the Women Healthcare Market . By the end projection of 2023, postmenopausal osteoporosis outdid the segment in the global market. Postmenopausal osteoporosis, increased focus on evolving medicinal treatments to postmenopausal osteoporosis by pharmaceuticals, and a higher incidence of osteoporosis fractures are some of the relevant drivers that addressed the part’s growth. In addition, the risk factors include old age and obesity the chances of developing osteoporosis in women. This sector is also expected to be the one with the highest CAGR in the course of the projection period.

The Proila category of the women's healthcare business is expected to increase at the fastest CAGR, by drug, throughout the projection period. The Women Healthcare Market is divided into medication categories, including EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, ORTHO-TRI-CY LO (28). Prolia is the market's fastest-expanding sector. In addition, Prolia held the largest market share in 2018. The rising demand for Prolia, driven by the increased prevalence of postmenopausal osteoporosis among women, is the primary driver of this market segment's growth.
Women Healthcare Market Regional Insights
North America dominated the worldwide Women Healthcare Market in 2023, accounting for the largest market share. The region is expected to maintain its current patterns during the projection period. Analyzing the primary factors anticipated to drive development, it is seen that growth of the target demographic of women seeking healthcare in the region is anticipated to be the major driver for the growth of this market. In addition, the increased prevalence of chronic diseases, customers’ shift towards safer procedures and minimally invasive surgeries, an increase in the acceptance of telemedicine, and others are also stimulating the growth of the market. The expansion of clinical trials also increases the funds allocated to research and development in North America, which, in turn, will enhance the sector’s revenues in women’s healthcare.

The increasing incidence of PCOS and postmenopausal osteoporosis, the increase in the median age of women giving birth for the first time and the increase in health care expenditure in the USA and Canada are some of the significant factors that will propel the demand in the Women Healthcare Market . In addition, American women’s positive perception of contraceptives and their ability to understand them greatly, together with easy access to modern contraceptives as compared to the developed nations, continues to propel the market in this segment.

For example, The National Cancer Institute as a part of the National Institutes of Health conducts research on ‘women’s cancer’ including breast cancer, ovarian cancer and cervical cancer. Also, the Planned Parenthood Federation of America provides and supports funds for family planning services, reproductive health, and sexual health education. The United States is expected to remain the largest regional market for the product by 2030 due to the rising concern for women’s health, awareness campaigns by the government, and an increase in research for the product. Based on the report made by the MMR research, all over the world, sixty-five per cent of women cannot ask for help, or they live in areas that are not served at all. This high incidence of healthcare is putting pressure on existing and new technologies to come up with more ways of treating patients as well as expanding the opportunities for the Women Healthcare Market enterprise in the country.

American-based Amgen is among the major players in the Women Healthcare Market . The prime markets for the operation of the company’s sales and marketing divisions are the United States and Europe. The firm distributes the Prolia while the Xgeva is used in the treatment of osteoporosis in postmenopausal women. These medications have experienced increasing year-by-year double digits both in value and volume aspects and they control the biggest portion of the market. There is also EVENITY from Amgen for osteoporosis in postmenopausal women and it has entered phase 3 of development. It is being created in parallel with UCB (Belgium). This has been made possible by the company’s strategic positioning and pursuit of the brand image, new product development, and innovation.

The European Women Healthcare Market remains an important segment of the healthcare industry that presents various services and goods aimed at solving the peculiarities of women’s health needs throughout their lives. It is characterized by a diverse spectrum of public and private healthcare systems, significant differences in healthcare expenditures, and a focus on the efficacy of the applied therapy. Some of the reasons for the market growth include higher incidence of diseases, people’s age, and the desire to avoid serious surgeries in women. Trends of technological advancements as well as embracing the use of surgical health information technologies are believed to have a large influence on the future of women’s health care in Europe.


Women Healthcare Market Scope: Inquire Before Buying



Global Women Healthcare Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 33.35 Bn.


Forecast Period 2024 to 2030 CAGR:
7.36%
Market Size in 2030:
US $ 54.83 Bn.


 Segments Covered:
by Drug
Prolia
XGEVA
EVISTA
Mirena
Zometa
Reclast/Aclasta
Minastrin 24 Fe
NuvaRing
FORTEO
Premarin
ACTONEL
ORTHO TRI-CY LO (28)
Other


by Application
Hormonal Infertility
Postmenopausal Osteoporosis
Endometriosis
Contraception
Polycystic Ovary Syndrome (PCOS)
Menopause
Other



Women Healthcare Market, by Region:
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Women Healthcare Market, Key Players
1. AbbVie, Inc
2. Pfizer, Inc
3. Teva Pharmaceutical Industries Ltd
4. Siemens
5. Hologic, Inc
6. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7. Abbott
8. F. Hoffmann-La Roche Ltd
9. Thermo Fisher Scientific Inc.
10. Koninklijke Philips N.V.
11. NeuroLogica Corp
12. Shimadzu Medical pvt. Ltd
13. Quest Diagnostics Incorporated
14. Sysmex India Pvt. Ltd
15. FUJIFILM Holdings Corporation
16. Bayer AG(Germany)
17. Allergan (Dublin)
18. Merck & Co., Inc (US)
19. Pfizer Inc. (US)
20. Amgen (US)
21. Agile Therapeutics Inc. (US)
22. Ferring Pharmaceuticals (US)
23. Mylan N.V. (US)
24. Lupin (India)
25. Blairex Laboratories (US)
26. Apothecus Pharmaceutical (US)

Frequently Asked Questions:
1] What segments are covered in the Global Women Healthcare Market report?
Ans. The segments covered in the Women Healthcare Market report are based on drugs and applications.

2] Which region held the largest Women Healthcare Market share in 2023?
Ans. The North American region held the largest Women Healthcare Market share in 2023 in which the U.S. was the leading country.

3] What is the expected Women's Healthcare Market size by 2030?
Ans. The Women Healthcare Market size is expected to reach US$ 54.83 Bn by 2030.

4] What was the opportunity of the Global Women Healthcare Market?
Ans. The role of technology & Global Initiatives in Expanding Access to Healthcare is an opportunity in the Global Women Healthcare Market.

5] What is the expected CAGR of the Global Women Healthcare Market during the forecast period?
Ans. The expected CAGR of the Women's Healthcare Market is 7.36 % during the forecast period.